Notably, data disclosed in relation to the initial public offering of Prime Medicine (https://primemedicine.com) suggest that ex vivo prime editing of human CD34+ HSPCs can be quite effective and may support treatment of certain blood disorders. The gene discussed is CD34; the disease is hematologic disorder.